.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,767,851

« Back to Dashboard

Claims for Patent: 7,767,851

Title:Ferric organic compounds, uses thereof and methods of making same
Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
Inventor(s): Kwok; David W. K. (Vancouver, CA), Stoynov; Nikolay Mintchev (Vancouver, CA)
Assignee: Panion & BF Biotech, Inc. (Nangang District, Taipei, TW)
Application Number:11/206,981
Patent Claims: 1. A solid form of ferric citrate having a formula of C.sub.6H.sub.5O.sub.7Fe and an intrinsic dissolution rate between 1.9 and 4.0 mg/cm.sup.2/min, as determined by the USP intrinsic dissolution assay in water, wherein the solid form of ferric citrate is synthesized by a method comprising: (a) adding an alkaline metal hydroxide solution to a ferric chloride solution; (b) isolating a ferric hydroxide precipitate; (c) forming a suspension of the ferric hydroxide precipitate in water; (d) adding citric acid to the suspension and forming a ferric-citric acid solution by heating said suspension with said citric acid; and (e) precipitating the solid form of ferric citrate by mixing the ferric-citric acid solution with an organic solvent.

2. The solid form of ferric citrate of claim 1, wherein the alkaline metal hydroxide is aqueous sodium hydroxide or aqueous potassium hydroxide.

3. The solid form of ferric citrate of claim 1, wherein the ferric chloride solution is an aqueous solution, or is prepared from ferric chloride hexahydrate.

4. The solid form of ferric citrate of claim 1, wherein the organic solvent is ethanol, methanol, butanol, acetone, isopropyl alcohol or tetrahydrofuran.

5. The solid form of ferric citrate of claim 1, wherein the compound has a BET active surface area exceeding 16 m.sup.2/g.

6. The solid form of ferric citrate of claim 1, wherein the compound is used for treating disorders responsive to ferric organic compound therapy.

7. The solid form of ferric citrate of claim 6, wherein the disorder is hyperphosphatemia or metabolic acidosis.

8. The solid form of ferric citrate of claim 7, wherein the dose for treating the disorder is 3 g/day to 6 g/day.

9. The solid form of ferric citrate of claim 1, wherein the compound is for oral administration as a tablet, powder, capsule, granule, troche or pill.

10. A pharmaceutical composition comprising the solid form of ferric citrate of claim 1 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein the solid form of ferric citrate has a BET active surface area exceeding 16 m.sup.2/g.

12. The pharmaceutical composition of claim 10, wherein the composition is used for treating disorders responsive to ferric organic compound therapy.

13. The pharmaceutical composition of claim 12, wherein the disorder is hyperphosphatemia or metabolic acidosis.

14. The pharmaceutical composition of claim 13, wherein the dose of the solid form of ferric citrate for treating the disorder is 3 g/day to 6 g/day.

15. The pharmaceutical composition of claim 10, wherein the composition is for oral administration as a tablet, powder, capsule, granule, troche or pill.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc